Investigative Sites

In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential. They explore why trial complexity continues to grow despite industry efforts toward efficiency and share strategies for reducing data burden while maintaining compliance.

Learn how increasing system complexity and patient-facing technologies are creating new burdens for clinical trial sites—and what vendors and sponsors can do to streamline operations and improve support.

Exploring how large-scale patient databases and AI analytics can accelerate site activation, strengthen recruitment, and improve trial design from the start.

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to high-quality, diverse research leadership.

Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site influence, patient engagement, and trial success.

As decentralized and hybrid trial models expand, eConsent is emerging as a critical tool for improving participant understanding, reducing site burden, and strengthening data integrity through digital automation, accessibility, and regulatory compliance.

Capturing insights from clinical research professionals on the key trends and challenges shaping drug development today, from those in clinical trial operations and site relationships, to technology and AI, and the evolving regulatory and policy terrain.

Learn how streamlined confidentiality agreements and consistent workflows can speed site activation and improve sponsor-site transparency.

Gain insight into how listening to site feedback and prioritizing engagement, training, and local patient understanding can drive smoother startups and stronger study outcomes.

Explore ways to reduce redundancy in site training by applying adult learning principles and focusing on enrollment and randomization essentials.

Discover how early site involvement, streamlined training, and AI-driven tools can simplify system complexity and enhance efficiency in clinical trials.

Learn how internal infrastructure, cultural buy-in, and workflow-focused technology choices can strengthen collaboration and reduce site burden in clinical trials.

Learn how integrated platforms, single sign-on tools, and streamlined training approaches can reduce site burden while supporting compliance and study startup.

Discover how reducing redundancy in feasibility processes and leveraging shared databases can improve collaboration and ease site burden.

At the 2025 SCRS Global Site Solutions Summit, site leaders shared insights on when and how to sell a clinical research site, stressing the importance of timing, cultural alignment, personal goals, and clear terms for long-term success.

In a breakout session at the 2025 SCRS Global Site Solutions Summit, industry leaders from SCRS, QCR, and Syneos Health discussed how sites can prioritize patient empowerment, strengthen community outreach, and collaborate with CROs and sponsors to secure resources for engagement initiatives.

Learn how the lack of integration across platforms creates complexity for sites and why holistic solutions are key to reducing data entry and system burden.

At the 2025 SCRS Global Site Solutions Summit, industry experts discussed how sites can balance culture, staffing, and training while expanding across multiple locations.

Explore how stronger collaboration and closed feedback loops can improve communication, change management, and site engagement in clinical trials.

Steve Rosenberg, CEO, uMotif, discusses the challenges sites face with eCOA, eConsent, and ePRO platforms and the support needed to reduce technical burdens.

Modernizing Clinical Trials: A Site-Centered Roadmap for the Future Simplifying startup, empowering sites through networks, and adopting evidence-based site selection frameworks can address enrollment bottlenecks, reduce dropout, and strengthen trial efficiency across the research ecosystem.

Michel van Harten, MD, CEO, myTomorrows; and Kyle McAllister, co-founder, CEO, Trially, discuss how artificial intelligence can reduce barriers for underrepresented patients and streamline prescreening and outreach to support clinical research participation.

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, describes how double-blind double-dummy design, site reminders, and patient engagement measures ensured high adherence with quarterly subcutaneous dosing in the NIMBLE trial.

Clinical trial enrollment and retention challenges, coupled with limited site resources, highlight the need for stronger site support, collaboration, and patient-centered trial models.

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, describes how double-blind double-dummy dosing, standardized assessments, and site training ensured protocol adherence and data integrity in the NIMBLE trial.